Work

A Phase I/II, multicenter, open-label study of REGN5668 (R5668; mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab or REGN4018 (R4018; MUC16 x CD3 bsAb) in patients with recurrent ovarian cancer (1309)

Year: 2023

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2023.06.212

Authors: Ira Winer, Anthony Shields, Oladapo Yeku, Joyce Liu, Mary Peterman, Tracey Rowlands, Suk-Young Yoo, Israel Lowy, N. Alice Yama-Dang, Priscila Goncalves, Glenn Kroog

Institutions: Wayne State University, The Barbara Ann Karmanos Cancer Institute, Massachusetts General Hospital, Dana-Farber Cancer Institute, Regeneron (United States)

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4386947945

FWCI:

Cites:

Cited by:

Related to: 10